A. D. Beadell Investment Counsel, Inc. Biogen Inc. Transaction History
A. D. Beadell Investment Counsel, Inc.
- $115 Million
- Q1 2024
A detailed history of A. D. Beadell Investment Counsel, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, A. D. Beadell Investment Counsel, Inc. holds 970 shares of BIIB stock, worth $218,880. This represents 0.18% of its overall portfolio holdings.
Number of Shares
970
Previous 970
-0.0%
Holding current value
$218,880
Previous $251,000
16.73%
% of portfolio
0.18%
Previous 0.24%
Shares
1 transactions
Others Institutions Holding BIIB
# of Institutions
1,047Shares Held
126MCall Options Held
1.37MPut Options Held
1.35M-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.74 Billion0.07% of portfolio
-
Primecap Management CO Pasadena, CA16.2MShares$3.66 Billion2.65% of portfolio
-
Black Rock Inc. New York, NY14.1MShares$3.19 Billion0.07% of portfolio
-
State Street Corp Boston, MA6.75MShares$1.52 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.17MShares$1.17 Billion0.68% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $32.5B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...